In particular, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway blockade using anti-PD-1 or anti-PD-L1 antibodies has elicited durable clinical responses in patients with cancer, presumably by normalizing imbalances in antitumor immunity (3). Here, CD274 is linked to cancer.